177 related articles for article (PubMed ID: 33218896)
21. Improved binding affinities of pyrrolidine derivatives as Mcl-1 inhibitors by modifying amino acid side chains.
Wan Y; Liu T; Li X; Chen C; Fang H
Bioorg Med Chem; 2017 Jan; 25(1):138-152. PubMed ID: 27810438
[TBL] [Abstract][Full Text] [Related]
22. Structure-based virtual screening, biological evaluation and biophysical study of novel Mcl-1 inhibitors.
Du J; Liu L; Liu B; Yang J; Hou X; Yu J; Fang H
Future Med Chem; 2020 Jul; 12(14):1293-1304. PubMed ID: 32397829
[No Abstract] [Full Text] [Related]
23. Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.
Wan Y; Dai N; Tang Z; Fang H
Eur J Med Chem; 2018 Feb; 146():471-482. PubMed ID: 29407973
[TBL] [Abstract][Full Text] [Related]
24. Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer.
Lee T; Christov PP; Shaw S; Tarr JC; Zhao B; Veerasamy N; Jeon KO; Mills JJ; Bian Z; Sensintaffar JL; Arnold AL; Fogarty SA; Perry E; Ramsey HE; Cook RS; Hollingshead M; Davis Millin M; Lee KM; Koss B; Budhraja A; Opferman JT; Kim K; Arteaga CL; Moore WJ; Olejniczak ET; Savona MR; Fesik SW
J Med Chem; 2019 Apr; 62(8):3971-3988. PubMed ID: 30929420
[TBL] [Abstract][Full Text] [Related]
25. Structural investigations on coumarins leading to chromeno[4,3-c]pyrazol-4-ones and pyrano[4,3-c]pyrazol-4-ones: New scaffolds for the design of the tumor-associated carbonic anhydrase isoforms IX and XII.
Bonardi A; Falsini M; Catarzi D; Varano F; Di Cesare Mannelli L; Tenci B; Ghelardini C; Angeli A; Supuran CT; Colotta V
Eur J Med Chem; 2018 Feb; 146():47-59. PubMed ID: 29407972
[TBL] [Abstract][Full Text] [Related]
26. Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors.
Lee T; Bian Z; Zhao B; Hogdal LJ; Sensintaffar JL; Goodwin CM; Belmar J; Shaw S; Tarr JC; Veerasamy N; Matulis SM; Koss B; Fischer MA; Arnold AL; Camper DV; Browning CF; Rossanese OW; Budhraja A; Opferman J; Boise LH; Savona MR; Letai A; Olejniczak ET; Fesik SW
FEBS Lett; 2017 Jan; 591(1):240-251. PubMed ID: 27878989
[TBL] [Abstract][Full Text] [Related]
27. Application of a Validated QSTR Model for Repurposing COX-2 Inhibitor Coumarin Derivatives as Potential Antitumor Agents.
Tugcu G; Sipahi H; Aydin A
Curr Top Med Chem; 2019; 19(13):1121-1128. PubMed ID: 31210111
[TBL] [Abstract][Full Text] [Related]
28. Design, Synthesis and Biological Evaluation of Novel 4-Substituted Coumarin Derivatives as Antitumor Agents.
An R; Hou Z; Li JT; Yu HN; Mou YH; Guo C
Molecules; 2018 Sep; 23(9):. PubMed ID: 30200625
[TBL] [Abstract][Full Text] [Related]
29. Novel inhibitors of human histone deacetylases: design, synthesis and bioactivity of 3-alkenoylcoumarines.
Seidel C; Schnekenburger M; Zwergel C; Gaascht F; Mai A; Dicato M; Kirsch G; Valente S; Diederich M
Bioorg Med Chem Lett; 2014 Aug; 24(16):3797-801. PubMed ID: 25042254
[TBL] [Abstract][Full Text] [Related]
30. Design, Synthesis and Structure-Activity Relationship Studies of Glycosylated Derivatives of Marine Natural Product Lamellarin D.
Zheng L; Gao T; Ge Z; Ma Z; Xu J; Ding W; Shen L
Eur J Med Chem; 2021 Mar; 214():113226. PubMed ID: 33582387
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents.
Abdizadeh T; Kalani MR; Abnous K; Tayarani-Najaran Z; Khashyarmanesh BZ; Abdizadeh R; Ghodsi R; Hadizadeh F
Eur J Med Chem; 2017 May; 132():42-62. PubMed ID: 28340413
[TBL] [Abstract][Full Text] [Related]
32. Synthesis, biological activity and multiscale molecular modeling studies of bis-coumarins as selective carbonic anhydrase IX and XII inhibitors with effective cytotoxicity against hepatocellular carcinoma.
Kurt BZ; Dag A; Doğan B; Durdagi S; Angeli A; Nocentini A; Supuran CT; Sonmez F
Bioorg Chem; 2019 Jun; 87():838-850. PubMed ID: 31003041
[TBL] [Abstract][Full Text] [Related]
33. Current developments of coumarin-based anti-cancer agents in medicinal chemistry.
Emami S; Dadashpour S
Eur J Med Chem; 2015 Sep; 102():611-30. PubMed ID: 26318068
[TBL] [Abstract][Full Text] [Related]
34. 3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation.
Abulwerdi FA; Liao C; Mady AS; Gavin J; Shen C; Cierpicki T; Stuckey JA; Showalter HD; Nikolovska-Coleska Z
J Med Chem; 2014 May; 57(10):4111-33. PubMed ID: 24749893
[TBL] [Abstract][Full Text] [Related]
35. Synthesis,
Goud NS; Kanth Makani VK; Pranay J; Alvala R; Qureshi IA; Kumar P; Bharath RD; Nagaraj C; Yerramsetty S; Pal-Bhadra M; Alvala M
Bioorg Chem; 2020 Apr; 97():103663. PubMed ID: 32106038
[TBL] [Abstract][Full Text] [Related]
36. Design and Synthesis of Novel Coumarin Conjugated Acetamides as Promising Anticancer Agents: An In Silico and In Vitro Approach.
Mamatha SV; Belagali SL; Bhat M; Kumbar VM
Anticancer Agents Med Chem; 2021; 21(11):1431-1440. PubMed ID: 32664844
[TBL] [Abstract][Full Text] [Related]
37. Rational Design of Coumarin Derivatives as CK2 Inhibitors by Improving the Interaction with the Hinge Region.
Zhang N; Chen WJ; Zhou Y; Zhao H; Zhong RG
Mol Inform; 2016 Jan; 35(1):15-8. PubMed ID: 27491649
[TBL] [Abstract][Full Text] [Related]
38. DNA-binding activity and cytotoxic and cell-cycle arrest properties of some new coumarin derivatives: a multispectral and computational investigation.
Khosravifar F; Dehghan G; Bidoki SK; Mahdavi M
Luminescence; 2020 Feb; 35(1):98-106. PubMed ID: 31475787
[TBL] [Abstract][Full Text] [Related]
39. Design and synthesis of 2-phenylpyrimidine coumarin derivatives as anticancer agents.
Lv N; Sun M; Liu C; Li J
Bioorg Med Chem Lett; 2017 Oct; 27(19):4578-4581. PubMed ID: 28888820
[TBL] [Abstract][Full Text] [Related]
40. Discovery of 3,5-Dimethyl-4-Sulfonyl-1
Zhu PJ; Yu ZZ; Lv YF; Zhao JL; Tong YY; You QD; Jiang ZY
J Med Chem; 2021 Aug; 64(15):11330-11353. PubMed ID: 34342996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
